Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07172347
Recruiting Phase 2

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

NCT07172347 · tracked via the Priya Life Science China tracker
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 2
Started
2025-10-31
Last updated
2026-01-02

Condition(s) studied

Non-segmental Vitiligo

Investigational drug(s) / intervention(s)

VC005 tablets →VC005 Tablets Placebo

VC005 tablets: VC005 groups repeat administration for 52 weeks

VC005 Tablets Placebo: VC005 Placebo groups repeat administration for 52 weeks

Study summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol. * The subject is between 18 and 70 years of age (including borderline values) , regardless of gender. Exclusion Criteria: * Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. * All hair in the vitiligo area on the face is white. * Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs. * Subjects who have previously received depigmentation treatment. * Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.

Primary outcome measure(s)

  • Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24 — Week 24

Trial sites (1)

FacilityCityRegionStatus
The Peking University People's Hospital Beijing Beijng Recruiting

More Jiangsu vcare pharmaceutical technology co., LTD trials in China

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. Recruiting
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects Starting soon
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Recruiting
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) Recruiting
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo Starting soon

Other trials for the same condition

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo Recruiting
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo Starting soon
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo Starting soon
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07172347 on ClinicalTrials.gov ↗ ← All trials in China